The trajectory of companies tied to Viagra's legacy presents a intricate investment landscape. While the initial success generated substantial gains, generic competition have significantly diminished sales . Investing in related pharmaceutical firms now requires a discerning assessment of intellectual property safeguards, evolving patient trends ,